Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
Genentech to pay Immunocore $100 million to codevelop bispecific solid tumor therapy
by Ryan Cross
November 22, 2018
| A version of this story appeared in
Volume 96, Issue 47
Genentech is paying $100 million in up-front and near-term payments to Immunocore to codevelop its experimental cancer therapy IMC-C103C. The drug candidate will be tested in clinical trials next year and targets a cancer antigen called melanoma-associated antigen A4 (MAGE-A4), which is found in multiple types of solid tumors.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter